DexCom Announces Upcoming Conference Presentations

By Business Wire,  February 25, 2014, 08:30:00 AM EDT


SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:

  • Steve Pacelli, EVP, Strategy and Corporate Development, will present an update on DexCom at the Raymond James & Associates' 35th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 4, 2014 at 3:25 p.m. (EST). The presentation, which will occur live at the JW Marriott Grande Lakes, will be concurrently webcast.
  • Steve Pacelli, EVP, Strategy and Corporate Development, will present an update on DexCom at the 26th Annual ROTH Conference in Laguna Niguel, California on Monday, March 10, 2014 at 4:30 p.m. (PDT). The presentation, which will occur live at the Ritz-Carlton, Dana Point, will be concurrently webcast.
  • Terry Gregg, Chief Executive Officer, will present an update on DexCom at the Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 11, 2014 at 1:00 p.m. (EDT). The presentation, which will occur live at the Loews Miami Hotel, will be concurrently webcast.

The link to each webcast will be available on the DexCom website at www.dexcom.com by navigating to "About", then "Investor Relations", and then "Events and Webcasts", and the presentations will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward-Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's annual report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission on February 20, 2014.

Source: DexCom, Inc.



This article appears in: News Headlines

Referenced Stocks: DXCM


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.15 0.02 ▲ 0.12%
FB $ 58.94 0.78 ▼ 1.31%
GE $ 26.56 0.44 ▲ 1.68%
QQQ $ 86.20 0.02 ▲ 0.02%
CSCO $ 23.21 0.18 ▲ 0.78%
MU $ 23.91 1.43 ▲ 6.36%
ZNGA $ 4.289 0.18 ▲ 4.36%
MSFT $ 40.01 0.39 ▼ 0.97%

As of 4/17/2014, 04:07 PM